Juno CEO and Co-founder steps down in wake of Celgene acquisition

pharmafile | April 27, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Juno, appointment, pharma 

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown it more than 500 employees, is to step down from his role now that his company has been acquired by Celgene in a $9 billion deal earlier this year, it has emerged.

Bishop has worked in the industry for more than three decades. Prior to his founding of Juno, he served in a range of executive roles, most recently as Executive in Residence at global private equity firm Warburg Pincus, a company with “significant investment experience” in the pharmaceutical and healthcare industries.

Before this, he acted as Executive Vice President and Chief Operating Officer at Dendreon, a Seattle-based biotech focusing on cancer immunotherapy treatment, and as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals.

Neither Bioshop nor Celgene have made any formal announcement on the departure. Just a week previously, the company revealed that it had elected Bishop to its Board of Directors. Mark J Alles, Chairman and Chief Executive Officer of Celgene commented on the decision: “The changes announced today strengthen corporate governance by refreshing our Board of Directors and improving strategic insight provided to management in areas critical to our future success.” […] “Hans is a pioneer in the field of cellular immunotherapy whose expertise will help Celgene lead in this extremely promising area of science.”

Juno’s Executive Vice President of Technical Operations Ann Lee will take over Celgene’s Seattle office, as well as Juno operations in the Seattle area.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content